nach oben

Erschienen in:

01.02.2012 | Original Article

Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication

verfasst von: Steffi Wilsky, Katharina Sobotta, Nadine Wiesener, Johanna Pilas, Nadine Althof, Thomas Munder, Peter Wutzler, Andreas Henke

Erschienen in: Archives of Virology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Coxsackievirus B3 (CVB3) is a human pathogen that causes acute and chronic infections, but an antiviral drug to treat these diseases has not yet been developed for clinical use. Several intracellular pathways are altered to assist viral transcription, RNA replication, and progeny release. Among these, fatty acid synthase (FAS) expression is increased. In order to test the potential of FAS inhibition as an anti-CVB3 strategy, several experiments were performed, including studies on the correlation of CVB3 replication and FAS expression in human Raji cells and an analysis of the time and dose dependence of the antiviral effect of FAS inhibition due to treatment with amentoflavone. The results demonstrate that CVB3 infection induces an up-regulation of FAS expression already at 1 h postinfection (p.i.). Incubation with increasing concentrations of amentoflavone inhibited CVB3 replication significantly up to 8 h p.i. In addition, suppression of p38 MAP kinase activity by treatment with SB239063 decreased FAS expression as well as viral replication. These data provide evidence that FAS inhibition via amentoflavone administration might present a target for anti-CVB3 therapy.

Nur mit Berechtigung zugänglich

Gupta S, Markham DW, Drazner MH, Mammen PP (2008) Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 5(11):693–706PubMedCrossRef

Badorff C, Knowlton KU (2004) Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193(2–3):121–126PubMedCrossRef

Martin U, Nestler M, Munder T, Zell R, Sigusch HH, Henke A (2004) Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions. Med Microbiol Immunol (Berl) 193(2–3):133–139

Heim A, Weiss S (2004) Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol 193(2–3):149–154PubMedCrossRef

Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 193(2–3):101–107PubMedCrossRef

Rabenau HF, Richter M, Doerr HW (2010) Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199(1):45–51PubMedCrossRef

Whitton JL, Cornell CT, Feuer R (2005) Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3(10):765–776PubMedCrossRef

Esfandiarei M, McManus BM (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3:127–155PubMedCrossRef

Vuorinen T, Vainionpaa R, Heino J, Hyypia T (1999) Enterovirus receptors and virus replication in human leukocytes. J Gen Virol 80(Pt 4):921–927PubMed

10.

Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL (1999) The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 155(4):1205–1215PubMedCrossRef

11.

Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T (1994) Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84(3):823–829PubMed

12.

Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M (1985) Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 56(2):651–654PubMed

13.

Jarasch N, Martin U, Zell R, Wutzler P, Henke A (2007) Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 12:1633–1643PubMedCrossRef

14.

Klingel K, McManus BM, Kandolf R (1995) Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 16(Suppl O):42–45PubMed

15.

Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM (1996) Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 70(7):4632–4645PubMed

16.

Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, Klingel K (1999) Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res 62(2):149–158PubMedCrossRef

17.

Magnani JW, Dec GW (2006) Myocarditis: current trends in diagnosis and treatment. Circulation 113(6):876–890PubMedCrossRef

18.

Henke A, Jarasch N, Wutzler P (2008) Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines 7(10):1557–1567PubMedCrossRef

19.

Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, McManus BM (2006) Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res 99(4):354–361PubMedCrossRef

20.

Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus B (2007) Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9(10):2358–2371PubMedCrossRef

21.

Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL (2004) Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency. Med Microbiol Immunol 193(2–3):83–90PubMedCrossRef

22.

Rassmann A, Henke A, Zobawa M, Carlsohn M, Saluz HP, Grabley S, Lottspeich F, Munder T (2006) Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol 87(Pt 9):2631–2638PubMedCrossRef

23.

Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S (2004) Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J Virol 78(8):4197–4206PubMedCrossRef

24.

Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11):4523–4530PubMedCrossRef

25.

Belov GA, Ehrenfeld E (2007) Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle 6(1):36–38PubMedCrossRef

26.

Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB, Whitton JL (2010) Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. J Virol 84(23):12110–12124PubMedCrossRef

27.

Van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ (1997) Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 16(12):3519–3532PubMedCrossRef

28.

Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC (1997) In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60(9):884–888PubMedCrossRef

29.

Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER (1999) Antiviral activities of biflavonoids. Planta Med 65(2):120–125PubMedCrossRef

30.

Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, Lin RC (2001) Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull 24(3):311–312PubMedCrossRef

31.

Lee JS, Lee MS, Oh WK, Sul JY (2009) Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 32(8):1427–1432PubMedCrossRef

32.

Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S (1996) A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 70(11):7811–7818PubMed

33.

Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL (2001) Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 75(5):2377–2387PubMedCrossRef

34.

Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH (2001) Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39(11):4093–4096PubMedCrossRef

35.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45PubMedCrossRef

36.

Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A (2010) Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol 23(4):369–376PubMedCrossRef

37.

Nissen E, Pauli G, Vollenbroich D (1997) WST-1 assay–a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Anim 33(1):28–29PubMedCrossRef

38.

Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK (2008) WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 73(3):211–215PubMedCrossRef

39.

Dowling S, Cox J, Cenedella RJ (2009) Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44(6):489–498PubMedCrossRef

40.

Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 20(12):2027–2035PubMedCrossRef

41.

Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53(2):414–422PubMedCrossRef

42.

King EM, Holden NS, Gong W, Rider CF, Newton R (2009) Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284(39):26803–26815PubMedCrossRef

43.

Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T (2007) The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases? Antiviral Res 76(2):150–158PubMedCrossRef

44.

Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410(6824):37–40PubMedCrossRef

45.

Huttunen P, Hyypia T, Vihinen P, Nissinen L, Heino J (1998) Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes. Virology 250(1):85–93PubMedCrossRef

46.

Tung WH, Sun CC, Hsieh HL, Wang SW, Horng JT, Yang CM (2007) EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK, JNK and NF-kappaB in vascular smooth muscle cells. Cell Signal 19(10):2127–2137PubMedCrossRef

47.

Guinea R, Carrasco L (1990) Phospholipid biosynthesis and poliovirus genome replication, two coupled phenomena. EMBO J 9(6):2011–2016PubMed

48.

Fogg MH, Teterina NL, Ehrenfeld E (2003) Membrane requirements for uridylylation of the poliovirus VPg protein and viral RNA synthesis in vitro. J Virol 77(21):11408–11416PubMedCrossRef

49.

Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL (2002) Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76(9):4430–4440PubMedCrossRef

50.

Knowles LM, Axelrod F, Browne CD, Smith JW (2004) A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 279(29):30540–30545PubMedCrossRef

51.

Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21(Suppl 3):S12–S23PubMed

52.

Ballinger A, Peikin SR (2002) Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440(2–3):109–117PubMedCrossRef

53.

Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64(6):2070–2075PubMedCrossRef

54.

Adhikari RP, Novick RP (2005) Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology 151(Pt 9):3059–3069PubMedCrossRef

55.

Chayakulkeeree M, Rude TH, Toffaletti DL, Perfect JR (2007) Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. Antimicrob Agents Chemother 51(10):3537–3545PubMedCrossRef

Titel: Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication
verfasst von: Steffi Wilsky
Katharina Sobotta
Nadine Wiesener
Johanna Pilas
Nadine Althof
Thomas Munder
Peter Wutzler
Andreas Henke
Publikationsdatum: 01.02.2012
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 2/2012
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-011-1164-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

The molecular biology of rotaviruses X: intercellular dissemination of rotavirus NSP4 requires glycosylation and is mediated by direct cell-cell contact through cytoplasmic extrusions

Risk factors associated with hepatitis C virus infection in an urban population of the State of Mexico

Complete genome sequence of a banana bract mosaic virus isolate infecting the French plantain cv. Nendran in India

Identification and characterization of blueberry latent spherical virus, a new member of subgroup C in the genus Nepovirus

Multiple polyadenylated RNA viruses detected in pooled cultivated and wild plant samples